

ABSTRACT OF THE DISCLOSURE

The present invention relates to certain 4-heteroaryl-3-heteroarylidene-2-indolinones compounds and their physiologically acceptable salts which modulate the activity 5 of protein kinases ("PKs"), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.

10